Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis announces results of Trek study

Sanofi-Aventis announces results of Trek study

11th December 2007

Sanofi-Aventis has announced the results of the Trek dose-ranging study of AVE5026, with the compound demonstrating a significant dose response in the prevention of venous thromboembolism (VTE) in patients undergoing total knee replacement surgery.

These results of the study that involved 705 patients in 19 countries worldwide were presented at the annual meeting of the American Society of Haematology

AVE5026, a new injectable anticoagulant, is a new form of ultra low molecular weight heparin with mainly anti-Xa activity administered to patients once a day subcutaneously.

Michael Rud Lassen, from the department of orthopaedics at Hillerod hospital, said: “The results of the TREK study are very promising and AVE5026 has a potential to become the new gold standard injectable therapy for VTE prevention.”

Shire has announced plans for a phase III clinical trial programme next year involving over 10,000 patients undergoing abdominal or orthopaedic surgery, or receiving chemotherapy.

The company forecasts submissions to regulatory authorities in 2010, with a submission for VTE prevention in medical patients planned for 2011.

In September 2007, Sanofi-Aventis published an update to its research and development pipeline, reporting developments in a number of areas, with phase IIb results suggesting that AVE5026 could succeed Lovenox.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.